NewcelX Ltd.

Going-concern clinical-stage cell-therapy company with ~3 quarters of cash, deeply negative returns and a recent reverse-merger.

Strengths

• Post-merger access to Kadimastem's T1D cell-therapy platform and a refreshed scientific advisory board
• Modest debt (D/E 0.05) leaves capital structure unlevered

Risks

• Explicit going-concern doubt: $2.2M cash (8th pct), 3.2-quarter runway, current ratio 0.76, $84.9M accumulated deficit
• Deeply negative returns (ROE -114%, ROA -73%) and identified material weaknesses in internal control

Notable findings

• Going concernThis raises substantial doubt about its ability to continue as a going concern
• Cash burnNegative free cash flow (-2.8M)
• Weak liquidityCurrent ratio 0.76 (<1)
• Material weakness● NewcelX has identified material weaknesses in its internal control over financial reporting
• Insider buyingInsider buying — 2 open-market buy(s) by 2 insider(s) (cluster of 2 insiders, ~$374,998, last 6mo) Form 4 ↗
• Pending merger● NewcelX may fail to realize some or all of the anticipated benefits of the proposed Merger